Concord Biotech Limited has scheduled a Board of Directors meeting on May 29, 2026. The primary agenda includes the review and approval of the audited standalone and consolidated financial results for the fourth quarter and the full financial year ending March 31, 2026. Additionally, the Board is expected to recommend a final dividend on equity shares for shareholder consideration at the upcoming Annual General Meeting.
Upcoming Board Meeting Details
Concord Biotech Limited has announced that a meeting of its Board of Directors is set to take place on Friday, May 29, 2026. This meeting is critical for reviewing the company’s financial performance for the final quarter and the concluding fiscal year of 2026.
Financial Results and Dividend Proposal
During the meeting, the Board will consider and approve the audited financial results for both standalone and consolidated entities for the period ending March 31, 2026. The audit report from the Statutory Auditors will also be reviewed. Furthermore, the Board plans to propose a final dividend on the company’s equity shares, which will be subject to approval by shareholders during the next Annual General Meeting.
Trading Window Update
In accordance with corporate governance policies regarding insider trading, the company has confirmed that the trading window for all designated persons and their immediate relatives remains closed. This restriction will continue until 48 hours after the declaration of the financial results for the quarter and year ended March 31, 2026.
Source: BSE
